Total Payments
$292,993
2024 Payments
$32,042
Companies
24
Transactions
817
Medicare Patients
2,382
Medicare Billing
$705,549
Payment Breakdown by Category
Other$231,672 (79.1%)
Travel$34,579 (11.8%)
Food & Beverage$13,288 (4.5%)
Consulting$12,349 (4.2%)
Education$1,104 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $219,730 | 161 | 75.0% |
| Travel and Lodging | $34,579 | 181 | 11.8% |
| Food and Beverage | $13,288 | 446 | 4.5% |
| Consulting Fee | $12,349 | 10 | 4.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,863 | 6 | 2.7% |
| Honoraria | $2,080 | 2 | 0.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,000 | 1 | 0.7% |
| Education | $1,104 | 10 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $102,790 | 255 | $0 (2021) |
| ABBVIE INC. | $67,636 | 138 | $0 (2024) |
| Theravance Biopharma, Inc. | $55,827 | 114 | $0 (2018) |
| Cumberland Pharmaceuticals, Inc. | $43,673 | 104 | $0 (2024) |
| Merck Sharp & Dohme LLC | $9,933 | 77 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $5,821 | 32 | $0 (2024) |
| Insmed, Inc. | $5,109 | 36 | $0 (2024) |
| Astellas Pharma US Inc | $574.11 | 16 | $0 (2024) |
| Becton, Dickinson and Company | $541.67 | 1 | $0 (2022) |
| Melinta Therapeutics, LLC | $409.41 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,042 | 91 | ABBVIE INC. ($19,563) |
| 2023 | $13,343 | 57 | ABBVIE INC. ($8,322) |
| 2022 | $25,345 | 70 | ABBVIE INC. ($17,491) |
| 2021 | $30,875 | 92 | AbbVie Inc. ($22,261) |
| 2020 | $30,352 | 91 | Allergan, Inc. ($18,786) |
| 2019 | $66,126 | 184 | Allergan Inc. ($49,180) |
| 2018 | $51,379 | 120 | Theravance Biopharma, Inc. ($28,555) |
| 2017 | $43,531 | 112 | Theravance Biopharma Inc. ($27,271) |
All Payment Transactions
817 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $19.89 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/17/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $26.26 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/16/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $27.07 | General |
| Category: ANTIFUNGALS | ||||||
| 12/09/2024 | Invivyd Inc | PEMGARDA (Biological) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/14/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: ANTIFUNGALS | ||||||
| 10/29/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/28/2024 | Invivyd Inc | PEMGARDA (Biological) | Food and Beverage | In-kind items and services | $22.44 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/10/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/08/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $29.55 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/07/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Respiratory | ||||||
| 10/01/2024 | Tactile Systems Technology Inc | Flexitouch Plus (Device), Entre Plus | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 09/30/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: Infections and Infectious Diseases | ||||||
| 09/26/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 09/24/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $79.99 | General |
| 09/24/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: Infectious Diseases | ||||||
| 09/18/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Vabomere | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: ANTIFUNGALS | ||||||
| 09/05/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: GI | ||||||
| 08/30/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/29/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Travel and Lodging | Cash or cash equivalent | $29.48 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 08/27/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/21/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 08/20/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 08/19/2024 | Cumberland Pharmaceuticals, Inc. | CALDOLOR (Drug) | Food and Beverage | In-kind items and services | $24.37 | General |
| Category: ANESTHESIOLOGY PAIN MANAGEMENT | ||||||
| 08/15/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: GI | ||||||
| 08/13/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $22.61 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 524 | 6,587 | $393,612 | $130,539 |
| 2022 | 9 | 563 | 8,830 | $508,868 | $159,649 |
| 2021 | 11 | 676 | 11,654 | $641,790 | $209,767 |
| 2020 | 12 | 619 | 11,392 | $597,416 | $205,593 |
Total Patients
2,382
Total Services
38,463
Medicare Billing
$705,549
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0875 | Injection, dalbavancin, 5 mg | Office | 2023 | 15 | 5,700 | $228,000 | $67,171 | 29.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 169 | 427 | $60,260 | $25,486 | 42.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 85 | 144 | $28,572 | $12,904 | 45.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 93 | 98 | $31,960 | $9,440 | 29.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 42 | 46 | $18,353 | $5,837 | 31.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 37 | 60 | $11,640 | $5,369 | 46.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 24 | 48 | $10,080 | $2,201 | 21.8% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 33 | 35 | $3,010 | $1,302 | 43.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 12 | $1,584 | $686.70 | 43.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 14 | 17 | $153.00 | $142.80 | 93.3% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2022 | 18 | 7,800 | $312,000 | $88,996 | 28.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 195 | 493 | $69,513 | $26,861 | 38.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 84 | 150 | $29,700 | $11,764 | 39.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 101 | 115 | $37,490 | $11,520 | 30.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 59 | 61 | $24,293 | $8,804 | 36.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 26 | 102 | $21,420 | $5,280 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 36 | 57 | $11,058 | $5,267 | 47.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 32 | 38 | $3,268 | $1,116 | 34.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 12 | 14 | $126.00 | $41.46 | 32.9% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2021 | 24 | 10,500 | $420,000 | $125,779 | 29.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 211 | 516 | $72,756 | $28,823 | 39.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 113 | 210 | $41,580 | $17,124 | 41.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 132 | 140 | $45,640 | $14,287 | 31.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 50 | 50 | $19,900 | $7,699 | 38.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 45 | 75 | $14,550 | $7,241 | 49.8% |
About Dr. Micah Jacobs, MD
Dr. Micah Jacobs, MD is a Infectious Disease healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1386845022.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Micah Jacobs, MD has received a total of $292,993 in payments from pharmaceutical and medical device companies, with $32,042 received in 2024. These payments were reported across 817 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($219,730).
As a Medicare-enrolled provider, Jacobs has provided services to 2,382 Medicare beneficiaries, totaling 38,463 services with total Medicare billing of $705,549. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease
- Location Pittsburgh, PA
- Active Since 05/30/2007
- Last Updated 05/08/2015
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1386845022
Products in Payments
- DALVANCE (Drug) $125,261
- VIBATIV (Drug) $83,751
- TEFLARO (Drug) $34,695
- AVYCAZ (Drug) $10,470
- Vibativ (Drug) $9,356
- ZERBAXA (Drug) $5,875
- NUZYRA (Drug) $5,821
- Arikayce (Drug) $5,109
- DIFICID (Drug) $715.62
- Rezzayo (Drug) $268.14
- Cresemba (Drug) $193.15
- CUBICIN RF (Drug) $175.87
- CALDOLOR (Drug) $163.02
- Fetroja (Drug) $162.54
- VOWST (Biological) $127.40
- NOXAFIL (Drug) $123.23
- Xerava (Drug) $87.64
- REBYOTA (Biological) $87.63
- ZINPLAVA (Biological) $65.83
- Kimyrsa (Drug) $61.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Pittsburgh
Dr. Yohei Doi, M.d, M.D
Infectious Disease — Payments: $107,084
Infectious Disease $107,084
Dr. Chiu-Bin Hsiao, M.d, M.D
Infectious Disease — Payments: $38,718
Infectious Disease $38,718
Madhu Chhanda Choudhary
Infectious Disease — Payments: $10,873
Infectious Disease $10,873
Stacy Lane, Do, DO
Infectious Disease — Payments: $9,605
Infectious Disease $9,605
Fernanda Silveira, Md, MD
Infectious Disease — Payments: $7,792
Infectious Disease $7,792
Dr. Elias Shattahi, M.d, M.D
Infectious Disease — Payments: $5,686
Infectious Disease $5,686